Shares of Amneal Pharmaceuticals, Inc. (AMRX) rose 3% in pre-market trading on Tuesday after the company announced two major positive developments: an upward revision of its adjusted profit forecast for 2024 and a strategic agreement to acquire Kashiv Biosciences for $1.1 billions.

<headquartered in New Jersey, this generic drug manufacturer has raised its full-year adjusted earnings per share forecast from the previous range of $0.42-$0.50 to $0.45-$0.52, reflecting confidence in the growth momentum of its core business. Meanwhile, Amneal has made an all-cash deal valued at $1.1 billion, aiming to significantly bolster its specialty drug pipeline by acquiring Kashiv Biosciences' innovative biologics platform under development. Market analysts point out that the synergy of these two initiatives could bring long-term value enhancement to Amneal. The acquisition of Kashiv is expected to expand its market share in the high-margin specialty drug sector, while the upward revision of profit guidance sends a positive signal to investors about improved operational efficiency by management. After the deal is completed, Kashiv's R&D team will be integrated into Amneal's innovation division to accelerate the commercialization of next-generation therapies.